Ravi Salgia to Clinical Trials as Topic
This is a "connection" page, showing publications Ravi Salgia has written about Clinical Trials as Topic.
Connection Strength
1.014
-
Smoking prevalence and association with sociodemographic variables in cancer clinical trial participants. Cancer. 2025 Jan 01; 131(1):e35560.
Score: 0.149
-
Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. J Thorac Oncol. 2019 10; 14(10):1718-1731.
Score: 0.105
-
Pathologic Considerations and Standardization in Mesothelioma Clinical Trials. J Thorac Oncol. 2019 10; 14(10):1704-1717.
Score: 0.104
-
Systemic therapies in the treatment of non-small-cell lung cancer brain metastases. Future Oncol. 2016; 12(8):1045-58.
Score: 0.082
-
MET as a drug target. Clin Adv Hematol Oncol. 2015 Jun; 13(6):351-3.
Score: 0.078
-
Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors. Cancer Med. 2014 Jun; 3(3):681-92.
Score: 0.072
-
Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor. J Thorac Oncol. 2012 Dec; 7(16 Suppl 5):S372-4.
Score: 0.066
-
Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. Target Oncol. 2012 Sep; 7(3):199-210.
Score: 0.065
-
Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor. J Thorac Oncol. 2011 Nov; 6(11 Suppl 4):S1810-1.
Score: 0.061
-
MET receptor tyrosine kinase. J Thorac Oncol. 2009 Nov; 4(11 Suppl 3):S1064-5.
Score: 0.053
-
EGFR-targeted therapeutics: focus on SCCHN and NSCLC. ScientificWorldJournal. 2008 Sep 21; 8:909-19.
Score: 0.049
-
Review of clinic trials: agents targeting c-Met. Rev Recent Clin Trials. 2007 May; 2(2):143-7.
Score: 0.045
-
A review of topoisomerase inhibition in lung cancer. Cancer Biol Ther. 2006 Dec; 5(12):1600-7.
Score: 0.044
-
c-Met inhibition. Clin Adv Hematol Oncol. 2006 Nov; 4(11):823-4.
Score: 0.043